Cart
sales@molnova.com
CA-4948
CAS No. 1801343-74-7
CA-4948( CA 4948 | CA4948 | AU-4948 | AU 4948 | AU4948 )
Catalog No. M12741 CAS No. 1801343-74-7
CA-4948 (AU-4948) is a novel potent, selective, orally bioavailable IRAK4 inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 40 | In Stock |
|
| 5MG | 65 | In Stock |
|
| 10MG | 110 | In Stock |
|
| 25MG | 200 | In Stock |
|
| 50MG | 335 | In Stock |
|
| 100MG | 500 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCA-4948
-
NoteResearch use only, not for human use.
-
Brief DescriptionCA-4948 (AU-4948) is a novel potent, selective, orally bioavailable IRAK4 inhibitor.
-
DescriptionCA-4948 (AU-4948) is a novel potent, selective, orally bioavailable IRAK4 inhibitor; shows in vivo activity in TLR4-induced cytokine release model, exhibits dose-dependent efficacy in ABC-DLBCL MYD88-L265P xenograft tumor models; a therapeutic agent for hematological cancers with dysregulated TLR/MYD88/IRAK4 signaling, induces tumor regression in an ABC-DLBCL xenograft model combined with Venetoclax.Blood Cancer Phase 1 Clinical(In Vitro):IRAK4-IN-7 has anti-cancer and anti-inflammatory activities, it can be used for cancer and inflammatory diseases treatment.
-
In Vitro——
-
In VivoIRAK4-IN-7 has anti-cancer and anti-inflammatory activities, it can be used for cancer and inflammatory diseases treatment.
-
SynonymsCA 4948 | CA4948 | AU-4948 | AU 4948 | AU4948
-
PathwayImmunology/Inflammation
-
TargetIRAK
-
RecptorIRAK
-
Research AreaCancer
-
IndicationBlood cancer
Chemical Information
-
CAS Number1801343-74-7
-
Formula Weight417.429
-
Molecular FormulaC21H19N7O3
-
Purity>98% (HPLC)
-
SolubilityDMSO : 13.89 mg/mL 33.28 mM;H2O : < 0.1 mg/mL
-
SMILESO=C(C1=CC=CC(C2=CC=C(N)N=C2)=N1)NC3=CN=C4C(OC(N5CCOCC5)=N4)=C3
-
Chemical Name6'-amino-N-(2-morpholinooxazolo[4,5-b]pyridin-6-yl)-[2,3'-bipyridine]-6-carboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.?Robert Booher, et al. 1534 Combination of IRAK4 Inhibitor CA-4948 with BCL2 Inhibitor Venetoclax Induces Tumor Regression in an ABC-DLBCL Xenograft Model. Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center).
molnova catalog
related products
-
AS 2444697
A potent, selective, orally bioavailable IRAK-4 inhibitor that potently inhibits human and rat IRAK-4 activity with subnanomolar order.
-
PF-06650833
PF-06650833 (PF06650833) is a potent and selective IRAK4 inhibitor with IC50 of 0.2 nM.
-
HG-12-6
HG-12-6 is a small-molecule inhibitor that bind preferentially to unphosphorylated IRAK4 with IC50 of 165.1 nM.
